Literature DB >> 20594930

Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Paul A Marks1.   

Abstract

There are eleven zinc dependent histone deacetylases (HDAC) in humans which have histones and many non-histone substrates. The substrates of these enzymes include proteins that have a role in regulation of gene expression, cell proliferation, cell migration, cell death, immune pathways and angiogenesis. Inhibitors of HDACs (HDACi) have been developed which alter the structure and function of these proteins, causing molecular and cellular changes that induce transformed cell death. The HDACi are being developed as anti-cancer drugs and have therapeutic potential for many non-oncologic diseases.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20594930      PMCID： PMC4043339          DOI： 10.1016/j.bbagrm.2010.05.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  139 in total

Review 1.  Thioredoxin and related molecules--from biology to health and disease.

Authors:  Christopher Horst Lillig; Arne Holmgren
Journal:  Antioxid Redox Signal       Date:  2007-01       Impact factor: 8.401

2.  Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10.

Authors:  Shurong Chang; Bryan D Young; Shijie Li; Xiaoxia Qi; James A Richardson; Eric N Olson
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

3.  Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?

Authors:  Terry J Gaymes; Rose Ann Padua; Marika Pla; Stephen Orr; Nader Omidvar; Christine Chomienne; Ghulam J Mufti; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2006-08       Impact factor: 5.852

4.  HDAC6-p97/VCP controlled polyubiquitin chain turnover.

Authors:  Cyril Boyault; Benoit Gilquin; Yu Zhang; Vladimir Rybin; Elspeth Garman; Wolfram Meyer-Klaucke; Patrick Matthias; Christoph W Müller; Saadi Khochbin
Journal:  EMBO J       Date:  2006-06-29       Impact factor: 11.598

Review 5.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

6.  Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.

Authors:  Weisheng Xu; Lang Ngo; Gisela Perez; Milos Dokmanovic; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-09       Impact factor: 11.205

7.  Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.

Authors:  Anupama Munshi; Toshimitsu Tanaka; Marvette L Hobbs; Susan L Tucker; Victoria M Richon; Raymond E Meyn
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

8.  Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.

Authors:  David Z Qian; Sushant K Kachhap; Spencer J Collis; Henk M W Verheul; Michael A Carducci; Peter Atadja; Roberto Pili
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

9.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

10.  Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

Authors:  Jennifer L Brogdon; Yongyao Xu; Susanne J Szabo; Shaojian An; Francis Buxton; Dalia Cohen; Qian Huang
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113
View more
  67 in total

1.  Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells.

Authors:  Anusha Chidambaram; Arunachalam Sekar; Kavya S H; Ramesh Kumar Chidambaram; Kalaiarasi Arunachalam; Senthilkumar G P; Ravikumar Vilwanathan
Journal:  Invest New Drugs       Date:  2017-08-03       Impact factor: 3.850

Review 2.  Zinc and neurogenesis: making new neurons from development to adulthood.

Authors:  Cathy W Levenson; Deborah Morris
Journal:  Adv Nutr       Date:  2011-03-10       Impact factor: 8.701

Review 3.  Histone Deacetylases in Bone Development and Skeletal Disorders.

Authors:  Elizabeth W Bradley; Lomeli R Carpio; Andre J van Wijnen; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

4.  Development of a histone deacetylase 6 inhibitor and its biological effects.

Authors:  Ju-Hee Lee; Adaickapillai Mahendran; Yuanshan Yao; Lang Ngo; Gisela Venta-Perez; Megan L Choy; Nathaniel Kim; Won-Seok Ham; Ronald Breslow; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-10       Impact factor: 11.205

Review 5.  Histone Deacetylases in Cartilage Homeostasis and Osteoarthritis.

Authors:  Lomeli R Carpio; Jennifer J Westendorf
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

6.  Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.

Authors:  Yue Luo; Hui Wang; Xipeng Zhao; Chao Dong; Fengmei Zhang; Gang Guo; Gongshe Guo; Xiaowei Wang; Simon N Powell; Zhihui Feng
Journal:  Toxicol Res (Camb)       Date:  2016-02-18       Impact factor: 3.524

7.  Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.

Authors:  Joanna Edyta Fraczek; Mathieu Vinken; Dirk Tourwé; Tamara Vanhaecke; Vera Rogiers
Journal:  Invest New Drugs       Date:  2011-03-29       Impact factor: 3.850

8.  An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.

Authors:  Katherine Ververis; Tom C Karagiannis
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

Review 9.  Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

Authors:  Manuela Terranova-Barberio; Scott Thomas; Pamela N Munster
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

Review 10.  Epigenetic therapy in gastrointestinal cancer: the right combination.

Authors:  Eihab Abdelfatah; Zachary Kerner; Nainika Nanda; Nita Ahuja
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.